PD-1 Blockade for Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation
Yi‐Bin Chen(Massachusetts General Hospital), Robin Joyce(Beth Israel Deaconess Medical Center), Jerome Ritz(Dana-Farber Cancer Institute), Jad Bsat(Dana-Farber Cancer Institute), Robert Redd(Harvard University), Oreofe O. Odejide(Dana-Farber Cancer Institute), Margaret A. Shipp(Broad Institute), Jeffrey L. Wong(Memorial Sloan Kettering Cancer Center), Yago Nieto(The University of Texas MD Anderson Cancer Center), Alex F. Herrera(City of Hope), Sanjay S. Patel(Brigham and Women's Hospital), Caron A. Jacobson(Dana-Farber Cancer Institute), Arnold S. Freedman(Otsuka (Japan)), Parastoo B. Dahi(Memorial Sloan Kettering Cancer Center), Philippe Armand(Harvard University), Scott J. Rodig(Brigham and Women's Hospital), Reid W. Merryman(Harvard University), Eric D. Jacobsen(Dana-Farber Cancer Institute), Ann S. LaCasce(Otsuka (Japan)), Jennifer L. Crombie(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Austin I. Kim(Dana-Farber Cancer Institute), Samuel Y. Ng(National Cancer Institute), Kimberly C. Coleman(Dana-Farber Cancer Institute)
Cited by 4
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k